Sage Journals: Discover world-class research

Abstract

Purpose:

The purpose of this investigation was to evaluate the ocular pharmacokinetic/pharmacodynamic (PK/PD) relationship for besifloxacin, moxifloxacin, and gatifloxacin using rabbit ocular PK data, along with in vitro minimum inhibitory concentration (MIC₉₀) values against methicillin- and ciprofloxacin-resistant Staphylococcus aureus (MRSA-CR) and Staphylococcus epidermidis (MRSE-CR).

Methods:

Rabbits received a topical instillation of Besivance™ (besifloxacin ophthalmic suspension, 0.6%), Vigamox^® (moxifloxacin hydrochloride ophthalmic solution, 0.5% as base), or Zymar^® (gatifloxacin ophthalmic solution, 0.3%), and ocular tissues and plasma were collected from 4 animals/treatment/collection time at 8 predetermined time intervals during the 24 h after dosing. Ocular levels of each agent were measured by LC/MS/MS, and PK parameters (C_max, T_max, and AUC_0–24) were determined. AUC_0–24/MIC₉₀ ratios were calculated for tears, conjunctiva, cornea, and aqueous humor using previously reported MIC₉₀ values for MRSA-CR and MRSE-CR.

Results:

All of the fluoroquinolones tested demonstrated rapid penetration into ocular tissues after a single instillation. Besifloxacin demonstrated the highest exposure in tear fluid, while exposure in conjunctiva was comparable for all 3 compounds. Peak concentrations of all fluoroquinolones in aqueous humor were at or below ∼1 μg/mL. In comparison with their MIC₉₀ values against MRSE-CR and MRSA-CR, besifloxacin achieved an AUC_0–24/MIC₉₀ ratio of ∼800 in tears, compared with values of ≤10 for moxifloxacin and gatifloxacin. In cornea, conjunctiva, and aqueous humor, the AUC_0–24/MIC₉₀ ratios were <10 for all compounds. However, in these tissues AUC_0–24/MIC₉₀ ratios for besifloxacin were 1.5- to 38-fold higher than moxifloxacin and gatifloxacin.

Conclusions:

In rabbits, besifloxacin demonstrates a nonclinical ocular PK profile characterized by high and sustained concentrations in tear fluid, resulting in AUC_0–24/MIC₉₀ ratios of ∼800 for ciprofloxacin-resistant MRSE and MRSA after a single administration. Although besifloxacin had the highest AUC_0–24/MIC₉₀ ratios for intraocular tissues, the ratios for all of the drugs were below the target values needed for effective bacterial killing of ciprofloxacin-resistant MRSE and MRSA. Taken together, these nonclinical data indicate that besifloxacin has a favorable ocular PK/PD profile, consistent with the reported clinical efficacy of besifloxacin in the treatment of bacterial conjunctivitis, and consistent with the profile needed for ocular surface sterilization.

Get full access to this article

View all access options for this article.

References

Hovding

Acute bacterial conjunctivitis. Acta Ophthalmol., 86:5–17. 2008.

Rose

Management strategies for acute infective conjunctivitis in primary care: a systematic review. Expert Opin. Pharmacother., 8:1903–1921. 2007.

Centers for Disease Control and Prevention (CDC). Outbreak of bacterial conjunctivitis at a college—New Hampshire, January-March, 2002. MMWR. Morb. Mortal. Wkly. Rep., 51:205–207. 2002.

Sheikh

, Hurwitz

Antibiotics versus placebo for acute bacterial conjunctivitis. Cochrane Database Syst. Rev., 2006CD001211.

Jensen

H.G.

, Felix

In vitro antibiotic susceptibilities of ocular isolates in North and South America. In Vitro Antibiotic Testing Group. Cornea, 17:79–87. 1998.

Brook

Anaerobic and aerobic bacterial flora of acute conjunctivitis in children. Arch. Ophthalmol., 98:833–835. 1980.

Gigliotti

, Williams

W.T.

, Hayden

F.G.

et al. Etiology of acute conjunctivitis in children. J. Pediatr., 98:531–536. 1981.

Leeming

J.P.

Treatment of ocular infections with topical antibacterials. Clin. Pharmacokinet., 37:351–360. 1999.

Hammond

R.W.

, Edmondson

Treatment of ocular bacterial infections: an update. J. Am. Optom. Assoc., 68:178–187. 1997.

10.

Kurokawa

, Hayashi

, Konishi

et al. Increasing ofloxacin resistance of bacterial flora from conjunctival sac of preoperative ophthalmic patients in Japan. Jpn. J. Ophthalmol., 46:586–589. 2002.

11.

Yamada

, Yoshida

, Hatou

et al. Mutations in the quinolone resistance determining region in Staphylococcus epidermidis recovered from conjunctiva and their association with susceptibility to various fluoroquinolones. Br. J. Ophthalmol., 92:848–851. 2008.

12.

Afshari

N.A.

, Ma

J.J.

, Duncan

S.M.

et al. Trends in resistance to ciprofloxacin, cefazolin, and gentamicin in the treatment of bacterial keratitis. J. Ocul. Pharmacol. Ther., 24:217–223. 2008.

13.

Grasbon

, Mino de

K.H.

, Klauss

[Coagulase-negative staphylococci in normal and chronically inflamed conjunctiva]

Ophthalmologe, 92:793–801. 1995.

14.

Ward

K.W.

, Lepage

J.F.

, Driot

J.Y.

Nonclinical pharmacodynamics, pharmacokinetics, and safety of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use. J. Ocul. Pharmacol. Ther., 23:243–256. 2007.

15.

Cambau

, Matrat

, Pan

X.S.

et al. Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli. J. Antimicrob. Chemother., 63:443–450. 2009.

16.

Proksch

J.W.

, Granvil

C.P.

, Siou-Mermet

et al. Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans. J. Ocul. Pharmacol. Ther., 25:335–343. 2009.

17.

Wright

D.H.

, Brown

G.H.

, Peterson

M.L.

et al. Application of fluoroquinolone pharmacodynamics. J. Antimicrob. Chemother., 46:669–683. 2000.

18.

Hyatt

J.M.

, McKinnon

P.S.

, Zimmer

G.S.

et al. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin. Pharmacokinet., 28:143–160. 1995.

19.

Craig

W.A.

Does the dose matter?

Clin. Infect. Dis., 33,Suppl 3:S233–S237. 2001.

20.

Nightingale

C.H.

Future in vitro and animal studies: development of pharmacokinetic and pharmacodynamic efficacy predictors for tissue-based antibiotics. Pharmacotherapy, 25:146S–149S. 2005.

21.

Wilhelmus

K.R.

Evaluation and prediction of fluoroquinolone pharmacodynamics in bacterial keratitis. J. Ocul. Pharmacol. Ther., 19:493–499. 2003.

22.

Madaras-Kelly

K.J.

, Ostergaard

B.E.

, Hovde

L.B.

et al. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrob. Agents Chemother., 40:627–632. 1996.

23.

Ambrose

P.G.

, Bhavnani

S.M.

, Owens

R.C.

Jr.

Clinical pharmacodynamics of quinolones. Infect. Dis. Clin. North Am., 17:529–543. 2003.

24.

Sugioka

, Fukuda

, Komoto

et al. Intraocular penetration of sequentially instilled topical moxifloxacin, gatifloxacin, and levofloxacin. Clin. Ophthalmol., 3:553–557. 2009.

25.

Levine

J.M.

, Noecker

R.J.

, Lane

L.C.

et al. Comparative penetration of moxifloxacin and gatifloxacin in rabbit aqueous humor after topical dosing. J. Cataract Refract. Surg., 30:2177–2182. 2004.

26.

Levine

J.M.

, Noecker

R.J.

, Lane

L.C.

et al. Aqueous penetration of gatifloxacin and levofloxacin into the rabbit aqueous humor following topical dosing. J. Ocul. Pharmacol. Ther., 20:210–216. 2004.

27.

Richman

, Zolezio

, Tang-Liu

Comparison of ofloxacin, gentamicin, and tobramycin concentrations in tears and in vitro MICs for 90% of test organisms. Antimicrob. Agents Chemother., 34:1602–1604. 1990.

28.

Robertson

S.M.

, Curtis

M.A.

, Schlech

B.A.

et al. Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans. Surv. Ophthalmol., 50,Suppl 1:S32–S45. 2005.

29.

Aihara

, Miyanaga

, Minami

et al. A comparison of fluoroquinolone penetration into human conjunctival tissue. J. Ocul. Pharmacol. Ther., 24:587–591. 2008.

30.

Donnenfeld

E.D.

, Schrier

, Perry

H.D.

et al. Penetration of topically applied ciprofloxacin, norfloxacin, and ofloxacin into the aqueous humor. Ophthalmology, 101:902–905. 1994.

31.

Akkan

A.G.

, Mutlu

, Ozyazgan

et al. Comparative tear concentrations of topically applied ciprofloxacin, ofloxacin, and norfloxacin in human eyes. Int. J. Clin. Pharmacol. Ther., 35:214–217. 1997.

32.

Wagner

R.S.

, Abelson

M.B.

, Shapiro

et al. Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissue. Arch. Ophthalmol., 123:1282–1283. 2005.

33.

McCulley

J.P.

, Caudle

, Aronowicz

J.D.

et al. Fourth-generation fluoroquinolone penetration into the aqueous humor in humans. Ophthalmology, 113:955–959. 2006.

34.

Holland

E.J.

, Lane

S.S.

, Kim

et al. Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty. Cornea, 27:314–319. 2008.

35.

Koch

H.R.

, Kulus

S.C.

, Roessler

et al. Corneal penetration of fluoroquinolones: aqueous humor concentrations after topical application of levofloxacin 0.5% and ofloxacin 0.3% eyedrops. J. Cataract Refract. Surg., 31:1377–1385. 2005.

36.

Solomon

, Donnenfeld

E.D.

, Perry

H.D.

et al. Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor. Ophthalmology, 112:466–469. 2005.

37.

Arnold

D.R.

, Granvil

C.P.

, Ward

K.W.

et al. Quantitative determination of besifloxacin, a novel fluoroquinolone antimicrobial agent, in human tears by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 867:105–110. 2008.

38.

Proksch

J.W.

et al. Association for research in vision & ophthalmology. Invest. Ophthalmol. Vis. Sci., 50:E-2673. 2009.

39.

United States Food and Drug Administration. Dermatologic and Ophthalmic Drugs Advisory Committee. Briefing Package for besifloxacin hydrochloride ophthalmic suspension for the treatment of bacterial conjunctivitis. Bausch and Lomb, Inc. www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4397b1-00-Index.htm. 2010 May 18.

40.

Tepedino

M.E.

, Heller

W.H.

, Usner

D.W.

et al. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr. Med. Res. Opin., 25:1159–1169. 2009.

41.

McDonald

M.B.

, Protzko

E.E.

, Brunner

L.S.

et al. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis. Ophthalmology, 116:1615–1623.e1. 2009.

42.

Mather

, Stewart

J.M.

, Prabriputaloong

et al. The effect of cataract surgery on ocular levels of topical moxifloxacin. Am. J. Ophthalmol., 138:554–559. 2004.

43.

Owen

G.R.

, Brooks

A.C.

, James

et al. A novel in vivo rabbit model that mimics human dosing to determine the distribution of antibiotics in ocular tissues. J. Ocul. Pharmacol. Ther., 23:335–342. 2007.

44.

Yagci

, Oflu

, Dincel

et al. Penetration of second-, third-, and fourth-generation topical fluoroquinolone into aqueous and vitreous humour in a rabbit endophthalmitis model. Eye, 21:990–994. 2007.

45.

Bowman

L.M.

, Si

, Pang

et al. Development of a topical polymeric mucoadhesive ocular delivery system for azithromycin. J. Ocul. Pharmacol. Ther., 25:133–139. 2009.

46.

Shirasaki

Molecular design for enhancement of ocular penetration. J. Pharm. Sci., 97:2462–2496. 2008.

47.

Ahmed

, Patton

T.F.

Importance of the noncorneal absorption route in topical ophthalmic drug delivery. Invest. Ophthalmol. Vis. Sci., 26:584–587. 1985.

48.

Acheampong

A.A.

, Shackleton

, John

et al. Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes. Drug Metab. Dispos., 30:421–429. 2002.

49.

Chien

D.S.

, Homsy

J.J.

, Gluchowski

et al. Corneal and conjunctival/scleral penetration of p-aminoclonidine, AGN 190342, and clonidine in rabbit eyes. Curr. Eye Res., 9:1051–1059. 1990.

50.

Speaker

M.G.

, Milch

F.A.

, Shah

M.K.

et al. Role of external bacterial flora in the pathogenesis of acute postoperative endophthalmitis. Ophthalmology, 98:639–649. 1991.

Ocular Pharmacokinetics/Pharmacodynamics of Besifloxacin,Moxifloxacin,and Gatifloxacin Following Topical Administration to Pigmented Rabbits

Abstract

Abstract

Purpose:

Methods:

Results:

Conclusions:

Get full access to this article

References